Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results
Retrieved on:
Wednesday, November 10, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Health, Department of Finance and Administration, Achievement, Tax, Director, Phase 3, Leadership, Derivative, Joint, CEO, Biopharmaceutical, Technetium-99m, Arm, Technology, RA, National, Food, Insurance, Dextran, Information technology, Administration, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Program, Cardinal, LLC, Board, Travel, Massachusetts General Hospital, A1, Company, Clinical study report, Small business, Q&A, Board of directors, NYSE, Massachusetts, Small Business Innovation Research, Brothers in Arms 2: Global Front, Patient, FDA, Molecular mass, Biopsy, Total, Fine chemical, Management, Pharmaceutical industry
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter and year-to-date for the period ended September 30, 2021.
Key Points:
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter and year-to-date for the period ended September 30, 2021.
- Total net revenues for the third quarter of 2021 were $96,000, compared to $268,000 for the same period in 2020.
- R&D expenses for the third quarter of 2021 were $1.0 million, compared to $1.4 million in the same period in 2020.
- Navidea ended the third quarter of 2021 with $7.2 million in cash and cash equivalents.